(SLC) 시세

Minutes posted from call, but behind a paywall. 

https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al

When the pigs at the trough get their fill we will have a
HMBL type run.
And the pause of ongoing dilution of course.

Let’s focus on TNXP, stick politics somewhere else & other subjects too.

It's important to remember that legacy holders have invested at or above 0.18 cents. If they are not following sidechannel’s progress, the reality they see is a thinly traded penny stock lingering near its all-time lows.

They phone their broker to sell the stock. Broker says, yeah, i

I think it’s very unprofessional for management to not inform investors of the closing of the lab including departure of scientists! This just continues to be full of surprises ……

ASNS: AI infrastructure stocks are getting hot coming off the massive $ORCL AI Infrastucture deal just announced.
$ASNS the cheapest microfloat AI Infrastructure stock. Top management. Starting to rip. Has recent upgrade from highly regarded Litchfield. Do not miss $ASNS.
$ASNS has 6K

ASNS: AI infrastructure stocks are getting hot coming off the massive $ORCL AI Infrastucture deal just announced.
$ASNS the cheapest microfloat AI Infrastructure stock. Top management. Starting to rip. Has recent upgrade from highly regarded Litchfield. Do not miss $ASNS.
$ASNS has 6K

ASNS: AI infrastructure stocks are getting hot coming off the massive $ORCL AI Infrastucture deal just announced.
$ASNS the cheapest microfloat AI Infrastructure stock. Top management. Starting to rip. Has recent upgrade from highly regarded Litchfield. Do not miss $ASNS.
$ASNS has 6K

suit,

Thanks for posting the MHRA link!
https://investorshub.advfn.com/uimage/uploads/2024/10/21/zqal[200.gif
https://investorshub.advfn.com/uimage/uploads/2024/10/24/nqdtigiphy.gif

That’s exactly the kind of regulatory support that Advent has provided wh

Pm'd

I agree with you NorCal. Either the current mgt delivers financing this year or just sell the mine as you suggested to a large mining co that can deliver results. Many of us are stuck with shares that have fallen to lows that are not even worth selling. Would like to see a rebound and recoup our or

CNSP, readying for a Bullish Hammer tomorrow… 
https://schrts.co/cBIMqiew

CNSP, readying for a Bullish Hammer tomorrow… 
https://schrts.co/cBIMqiew

CNSP, readying for a Bullish Hammer tomorrow… 
https://schrts.co/cBIMqiew

Lets see 1.50 tomorrow or lower boys! Jam it at open! Lets roll $$$$$$

Theory, Approval of DCVax is near!

Yup, that's the way I understand it. Whether the contract is paid up front or on performance, the revenue is recognized when earned and deferred revenue is reduced to match. Good example with the labor-based contract. Same principle. You make a good point about the intellectual property. If this is

Statutes and regulations will always trump guidances, assuming the statutes or regulations address the issue the guidance is addressing. The reason agencies issue guidance is because the statutes and regulations haven't addressed the issue.

So, if you can find an FDA statute or regula

Statutes and regulations will always trump guidances, assuming the statutes or regulations address the issue the guidance is addressing. The reason agencies issue guidance is because the statutes and regulations haven't addressed the issue.

So, if you can find an FDA statute or regula

3331 has been restricted to one post per day:

BIEL HITS COPPER "IN THE BLINK OF AN EYE" WHEN THE FOLLOWING OCCURS!

pps > .001 after management drops some positive hints. The Golden Cross (already achieved) and Blue Sky Breakout will get the technicians/chartists attenti

https://cms.mhra.gov.uk/mhra/mia/uk-miaimp-54923

Oh you are talking about this MIA. Unfortunately, i only see ADVENT on this MIA. No sight of NWBO at all. Like i said congrats to LP not NWBO.


https://find-and-update.company-information.service.gov.uk/company

This is a response to Missling’s LinkedIn post by a VERY educated and qualified senior vice president of Red Nucleus who manages and provides strategic oversight and tactical back up for clinical teams.  He seems to think Blarcamesine  could likely work better than the study results show.